Age-related Macular Degeneration (AMD) Drugs Market Size, Share, Forecast Report 2026 to 2035
Segmentation of Age-related Macular Degeneration (AMD) Drugs Market :
Age-related Macular Degeneration (AMD) Drugs Market by Products -
- Lucentis
- Eylea & Eylea HD
- Vabysmo
- Syfovre
- Other Products
-Drugs-Market-Segmentation-Analysis.webp "Age-related Macular Degeneration (AMD) Drugs Market Segmentation Analysis")
Age-related Macular Degeneration (AMD) Drugs Market by Molecules -
- Ranibizumab
- Aflibercept
- Faricimab
- Pegcetoplan
- Other Molecules
Age-related Macular Degeneration (AMD) Drugs Market by Type of AMD -
- Wet AMD
- Dry AMD
Age-related Macular Degeneration (AMD) Drugs Market by Type of Approval type -
- Biologic
- Biosimilar
Age-related Macular Degeneration (AMD) Drugs Market by End User -
- Hospitals
- Specialty Centers
- Long-Term Care Facilities
Age-related Macular Degeneration (AMD) Drugs Market by Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Age-related Macular Degeneration (AMD) Drugs Market Snapshot
Chapter 4. Global Age-related Macular Degeneration (AMD) Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2026-2035
4.8. Global Age-related Macular Degeneration (AMD) Drugs Market Penetration & Growth Prospect Mapping (US$ Mn), 2022-2035
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2025 to 2035)
4.10. Use/impact of AI on Age-related Macular Degeneration (AMD) Drugs Industry Trends
Chapter 5. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. Market Share by Products,2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Products:
5.2.1. Lucentis
5.2.2. Eylea & Eylea HD
5.2.3. Vabysmo
5.2.4. Syfovre
5.2.5. Other Products
Chapter 6. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 2: By Molecules, Estimates & Trend Analysis
6.1. Market Share by Molecules,2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Molecules:
6.2.1. Ranibizumab
6.2.2. Aflibercept
6.2.3. Faricimab
6.2.4. Pegcetoplan
6.2.5. Other Molecules
Chapter 7. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 3: By Type of AMD, Estimates & Trend Analysis
7.1. Market Share by Type of AMD,2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Type of AMD:
7.2.1. Wet AMD
7.2.2. Dry AMD
Chapter 8. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 4: By Approval type, Estimates & Trend Analysis
8.1. Market Share by Approval type,2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Approval type:
8.2.1. Biologic
8.2.2. Biosimilar
Chapter 9. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 5: By End Users, Estimates & Trend Analysis
9.1. Market Share by End Users,2025 & 2035
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following End Users:
9.2.1. Hospitals
9.2.2. Specialty Centers
9.2.3. Long-Term Care Facilities
Chapter 10. Age-related Macular Degeneration (AMD) Drugs Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Age-related Macular Degeneration (AMD) Drugs Market, Regional Snapshot 2022 - 2035
10.2. North America
10.2.1. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022 - 2035
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2022 - 2035
10.2.3. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2022 - 2035
10.2.4. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2022 - 2035
10.2.5. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2022 - 2035
10.2.6. North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2022 - 2035
10.3. Europe
10.3.1. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022 - 2035
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2022 - 2035
10.3.3. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2022 - 2035
10.3.4. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2022 - 2035
10.3.5. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2022 - 2035
10.3.6. Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2022 - 2035
10.4. Asia Pacific
10.4.1. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022 - 2035
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2022 - 2035
10.4.3. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2022 - 2035
10.4.4. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2022 - 2035
10.4.5. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By Approval type, 2022 - 2035
10.4.6. Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By End Users, 2022 - 2035
10.5. Latin America
10.5.1. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022 - 2035
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2022 - 2035
10.5.3. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2022 - 2035
10.5.4. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2022 - 2035
10.5.5. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2022 - 2035
10.5.6. Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2022 - 2035
10.6. Middle East & Africa
10.6.1. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2022 - 2035
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2022 - 2035
10.6.3. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2022 - 2035
10.6.4. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2022 - 2035
10.6.5. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2022 - 2035
10.6.6. Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2022 - 2035
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Regeneron Pharmaceuticals Inc. (US)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Bayer AG (Germany)
11.2.3. F. Hoffmann-La Roche AG (Switzerland)
11.2.4. Novartis AG (Switzerland)
11.2.5. Apellis Pharmaceuticals, Inc. (US)
11.2.6. Coherus BioSciences, Inc. (US)
11.2.7. Astellas Pharma Inc. (Japan)
11.2.8. Biogen (US)
11.2.9. STADA Arzneimittel AG (Germany)
11.2.10. Formycon AG (Germany)
11.2.11. Biocon. (India)
11.2.12. Outlook Therapeutics, Inc. (US)
11.2.13. Intas Pharmaceuticals Ltd. (India)
11.2.14. Teva Pharmaceutical Industries Ltd. (Israel)
11.2.15. Chengdu Kanghong Biotech Company (China)
11.2.16. Sandoz Group AG (Switzerland)
11.2.17. Stealth BioTherapeutics Inc. (US)
11.2.18. Ocular Therapeutix, Inc. (US)
11.2.19. Opthea Limited, Inc. (Australia)
11.2.20. Kodiak Sciences Inc. (US)
11.2.21. Innovent Biologics, Inc. (China)
11.2.22. Bio-Thera Solution Inc. (China)
11.2.23. Alvotech (Iceland)
11.2.24. Alteogen Inc. (South Korea)
11.2.25. Shanghai Henlius Biotech, Inc. (China)
11.2.26. Amgen Inc. (US)
11.2.27. Ocumension Therapeutics. (China)
11.2.28. Adverum Biotechnologies, Inc. (US)
11.2.29. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 11.21 Bn in 2025 and is predicted to reach USD 27.96 Bn by the year 2035.
Age-related Macular Degeneration (AMD) Drugs Market is expected to grow at an 9.7% CAGR during the forecast period for 2026-2035.
Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, In
The Age-related Macular Degeneration (AMD) Drugs Market includes five segments Products, Molecules, Type of AMD, Approval type, and End-User, lucentis, eylea & eylea HD, vabysmo, syfovre, other products.
North American region is leading the Age-related Macular Degeneration (AMD) Drugs Market.